Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1992-10-8
|
pubmed:abstractText |
The efficiency and side-effects of tiaprofenic acid, mefenamic acid and placebo were compared in the treatment of primary dysmenorrhoea. The trial was a double-blind prospective randomized 3-way crossover study during 6 successive menstrual cycles following a 2-cycle run-in period and involved 50 women with primary dysmenorrhoea selected from 96 volunteers between 16 and 35 years of age. Overall pain was significantly less (p less than 0.05) on treatment with tiaprofenic acid than on treatment with mefanemic acid, placebo, or the women's usual treatments. Both active treatments were well tolerated but more side-effects were reported during treatment with mefenamic acid.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0004-8666
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
165-8
|
pubmed:dateRevised |
2009-11-11
|
pubmed:meshHeading |
pubmed-meshheading:1520205-Adolescent,
pubmed-meshheading:1520205-Adult,
pubmed-meshheading:1520205-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:1520205-Double-Blind Method,
pubmed-meshheading:1520205-Dysmenorrhea,
pubmed-meshheading:1520205-Female,
pubmed-meshheading:1520205-Humans,
pubmed-meshheading:1520205-Mefenamic Acid,
pubmed-meshheading:1520205-Propionic Acids,
pubmed-meshheading:1520205-Prospective Studies,
pubmed-meshheading:1520205-Treatment Outcome
|
pubmed:year |
1992
|
pubmed:articleTitle |
A comparison of tiaprofenic acid, mefenamic acid and placebo in the treatment of dysmenorrhoea in general practice.
|
pubmed:affiliation |
Department of General Practice, Otago Medical School, Dunedin, New Zealand.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|